Athira Pharma, Inc.

Athira Pharma, Inc.

Biotechnology • Healthcare • Bothell, WA, United States • ATHA (NCM)

Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.

425 620 8501 18706 North Creek Parkway, Bothell, WA 98011, United States Wikipedia

Stock Performance (90 Days)

Data through Dec 29, 2025
Layoff Events
Earnings Calls
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Earnings Call Transcripts

View All →
Q4 2025 Neutral
Nov 6, 2025

Athira Pharma, Inc. announced its financial results for the quarter ended September 30, 2025, through a press release issued on November 6, 2025. The company also detailed its various official communication channels for public disclosure, including SEC filings, websites, and social media platforms.

Recent News

Worthington, Athira Pharma general counsel, sells $6k in ATHA stock - Investing.com
Investing.com • Jan 6
Athira Pharma recovers from Alzheimer’s failure with breast cancer pivot and $90M investment - GeekWire
GeekWire • Dec 18
Athira Pharma Stock Shot Up 60% Today – What’s Triggering The Super Rally? - Stocktwits
Stocktwits • Dec 18
Is It Too Late to Buy Athira Pharma Inc. Stock? - timothysykes.com
timothysykes.com • Dec 18
Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million - GlobeNewswire
GlobeNewswire • Dec 18

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Athira Pharma, Inc. had layoffs?
No layoff events have been recorded for Athira Pharma, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Athira Pharma, Inc. have?
Athira Pharma, Inc. has approximately 26 employees.
What industry is Athira Pharma, Inc. in?
Athira Pharma, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Athira Pharma, Inc. a publicly traded company?
Yes, Athira Pharma, Inc. is publicly traded under the ticker symbol ATHA on the NCM. The company has a market capitalization of approximately $0.03 billion.
Where is Athira Pharma, Inc. headquartered?
Athira Pharma, Inc. is headquartered in Bothell, WA, United States at 18706 North Creek Parkway, Bothell, WA 98011, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.